Skip Navigation LinksHome > Collections > Oral MS Drugs

Oral MS Drugs

Created:   1/30/2012
Contains:  22 items

Show
Previous of 2 Next

PML in Suspected MS Patient Taking Fingolimod Raises FDA Concerns

Free Access
PDF
+ Favorites
Request Permissions

PML Reported in Patients Taking Psoriasis Compounds Sharing Ingredient with Oral MS Drug

Free Access
PDF
+ Favorites
Request Permissions

With New Oral Ms Drug, New Therapeutic Options

Free Access
PDF
+ Favorites
Request Permissions

Citing Possible Heart Risks, FDA Recommends Increased Monitoring, Tighter Indications, for MS Patients Prescribed Fingolimod

Free Access
PDF
+ Favorites
Request Permissions

Health Officials Launch Investigation in Deaths of Patients Taking Fingolimod

Free Access
PDF
+ Favorites
Request Permissions

News from ECTRIMS/ACTRIMS Fifth Triennial Conference: MS Drugs Take Center Stage at ECTRIMS/ACTRIM: Weighing their Pros and Cons

Free Access
PDF
+ Favorites
Request Permissions

A New Oral Drug for MS: How Does it Compare?

Free Access
PDF
+ Favorites
Request Permissions

MS Drugs are Expensive, Yes, But Are They Cost-Effective?

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: A Report Card on Neurological Conditions

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Oral Laquinimod Reportedly Shows MS Disability

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Fingolimod Heart Effects are Mild, Transient, and Usual Asymptomatic

Free Access
PDF
+ Favorites
Request Permissions

Skyrocketing MS Drug Prices Hit Patients Hard, Prompting Compliance Problems

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves First MS Oral Therapy

Free Access
PDF
+ Favorites
Request Permissions

Trialists Debate: Are Randomized Placebo Controlled Trials Always Ethical?

Free Access
PDF
+ Favorites
Request Permissions

MS Experts Highlight Favorite Papers on MS — From Predicting the Course of Disease to Comparing New to Standard Therapies

Free Access
PDF
+ Favorites
Request Permissions

For Relapsing MS Patients, Oral Adjunctive Teriflunoide Offers Additional Benefit Over Glatiramer on MRI Parameters

Free Access
PDF
+ Favorites
Request Permissions

Fingolimod Found to Significantly Reduce Inflammation in Brains of MS Patients with Relapsing‐Remitting Disease

Free Access
PDF
+ Favorites
Request Permissions

TWO ORAL THERAPIES FOUND EFFECTIVE FOR MS

Free Access
PDF
+ Favorites
Request Permissions

Fingolimod Suppresses Disease Activity in Relapsing‐Remitting MS: But Safety Concerns Are Identified

Free Access
PDF
+ Favorites
Request Permissions

Aaron Miller, MD: Course, Prognosis Remain Challenges in MS Research

Free Access
PDF
+ Favorites
Request Permissions
Show
Previous of 2 Next
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.